Analyst Daniel Brennan of TD Cowen maintained a Buy rating on Natera (NTRA – Research Report), retaining the price target of $195.00.
Daniel Brennan has given his Buy rating due to a combination of factors that highlight Natera’s strong performance and potential for growth. The company’s guidance for 2025 sales is notably higher than consensus estimates, suggesting potential upside. Additionally, the gross margin guidance exceeded expectations, although there is an increase in operating expenses, primarily in sales and marketing.
Signatera, one of Natera’s key products, showed significant growth in both units and average selling price, with expectations for continued strong performance in the upcoming quarters. The company’s early cancer detection initiatives also show promise, with new data indicating potential improvements in performance. Furthermore, Natera’s Women’s Health segment continues to outperform, contributing significantly to the company’s quarterly upside, with improving payment rates and a path to higher average selling prices in Carrier Screening.
According to TipRanks, Brennan is a 5-star analyst with an average return of 12.2% and a 45.52% success rate. Brennan covers the Healthcare sector, focusing on stocks such as Natera, Exact Sciences, and GeneDx Holdings.
In another report released on February 25, Canaccord Genuity also maintained a Buy rating on the stock with a $180.00 price target.